AGS Therapeutics Strengthens its Patent Portfolio on MicroalgaeExtracellular Vesicles (MEVs) with an International PatentApplication on the use of MEVs to deliver biological agents to thebrain by the intranasal route of administration.

7 May 2024

PARIS, FRANCE, May 7, 2024 – AGS Therapeutics, a preclinical-stage biotech company pioneering microalgae extracellular vesicles (MEV) as a new, universal delivery system, announced the recent publication of its PCT International Application No. PCT/EP2023/078634 – Publication – WO 2024/088808, titled Extracellular Vesicles from Microalgae, their Biodistribution upon Intranasal Administration, and Uses Thereof.
Thanks to their rare and natural capacity to overcome certain stringent biological barriers, MEVs can be used to deliver payloads to tissues and organs which have been so far either difficult or impossible to access by current alternative systems like LNPs, viral gene therapy vectors, or mammalian EVs. The blood-brain-barrier (BBB), a natural obstacle that protects the brain from agents arriving from the blood, is a canonical example of such stringent barriers. So much so, that efforts to overcome the BBB have consumed focus and large amounts of ressources for decades, and continue doing so today. To know more